Access to already-made obe-cel for B-cell ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This program provides access to an already-made dose of obe-cel (a type of CAR T-cell therapy) for patients whose manufactured product didn't meet the usual standards but is still considered safe and appropriate by their doctor and the study team. It's for people with a type of blood cancer called B-cell ALL that has come back or not responded to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with B-cell acute lymphoblastic leukemia (ALL – a type of blood cancer) that has returned or not responded to previous treatments.
- Your doctor had already planned to treat you with a CAR T-cell therapy called obe-cel, but the final manufactured dose did not meet the usual release standards.
- Your doctor and the study team agreed that the made dose is still safe and acceptable to use for you.
- Making a new dose (by collecting your cells again) is not considered appropriate for you by your doctor.
- You are medically stable enough to receive the treatment, and you are not participating in another interventional research trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell acute lymphoblastic leukemia who have achieved their first complete remission after standard chemotherapy. The goal is to see if this therapy can keep the leukemia from coming back.
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
This trial tests a new CAR T-cell therapy (obecabtagene autoleucel) given as a consolidation treatment after initial remission to prevent relapse in people with high-risk B-cell ALL. It's for patients who have achieved first remission but still have high-risk features in their leukemia.
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
This study provides access to a CAR T-cell therapy (a treatment that uses your own immune cells to fight cancer) for people with certain types of lymphoma who have no other good treatment options. The therapy is available even though it did not meet commercial standards, but it passed safety checks for this study.
This trial tests a new treatment using immune cells from donated umbilical cord blood to fight a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). The cells are engineered to target and kill cancer cells, which may help even if other treatments haven't worked.
Hear when a new Lymphoblastic Leukemia, Acute Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.